Objective: The objective of this study was to determine the timecourse of computed tomography (CT) contrast enhancement of an iodinated blood-pool contrast agent. Methods: Five C57BL/6 mice were anesthetized, imaged at baseline, and given an iodinated blood-pool contrast agent. Micro-CT scans were acquired at 0, 0.25, 0.5, 1, 2, 4, 8, and 24 hours after injection. The mean CT number was determined in a region of interest in 7 organs. Results: The CT contrast enhancement was plotted as a function of time for each organ. We identified an imaging window immediately after injection suitable for visualizing the vascular system and a second imaging window at 24 hours for visualizing liver and spleen. Conclusions: A single injection of the blood-pool contrast agent can be used for dual-phase investigations of the vasculature (t ϭ 0 hours) and liver (t ϭ 24 hours), which can be applied to studies of liver tumors or disease.
H igh-resolution imaging techniques for small animal models have evolved into powerful research tools that can be used noninvasively in vivo. Microcomputed tomography offers high-resolution volumetric images with isotropic voxels in relatively short scan times.
1,2 Images of bony structures have high contrast and exquisite detail; however, the contrast between different soft tissues or blood vessels is inherently poor in computed tomography (CT) images.
1 To improve the visualization of abdominal organs and the vasculature, highly attenuating exogenous contrast agents are used.
After intravenous injection, nonionic extracellular water-soluble agents, such as the iodinated agents typically used for clinical evaluations, clear from the vessels within a few minutes. These agents are cleared via the kidneys and could be of use in studies of renal structure and function.
2,3 Imaging the vasculature of animal models using micro-CT will not be possible with these agents because the majority of commercially available micro-CT scanners are not fast enough to capture the images before the contrast media is cleared from the blood. Recent advances in micro-CT technology have resulted in scanners that can produce volumetric images in 1-8 seconds 4 ; however, the use of rapidly clearing agents still poses problems because the first-pass phase of an extracellular intravenous contrast agent is only contained within the vasculature for a few heartbeats. If the image is not acquired at the appropriate time, a second acquisition (requiring a second contrast injection) would be necessary but may not be feasible because of renal toxicity caused by excessive amounts of iodine collecting in the kidneys.
For applications requiring the visualization of the vasculature, such as angiography, studies of atherosclerosis, and tumor characterization, a contrast agent with increased vascular residence time would be beneficial. A number of different approaches have been taken to produce a blood-pool contrast agent for CT. A water-soluble macromolecular agent (dysprosium-DTPA-dextran) described by Vera and Mattrey 5 is reported to provide blood-pool contrast enhancement for up to 45 minutes. 5 Alternatively, oil emulsions of ethiodol (Savage Laboratories, Melville, NY) remain intravascular for 20 minutes after injection in phantom studies of excised canine hearts 6 and in rabbits. 7 Liposomal encapsulation of iohexol
